Core Viewpoint - The company, Gilead Sciences-B (01672), has seen its stock price increase by over 7%, currently trading at 11.62 HKD with a transaction volume of 56.46 million HKD, following the announcement of a share buyback plan worth up to 300 million HKD [1] Group 1: Share Buyback Announcement - The board of directors has decided to exercise the buyback authorization and will repurchase shares in the open market based on market conditions [1] - The company plans to utilize a maximum of 300 million HKD for the proposed share buyback [1] Group 2: Clinical Data and Future Plans - Dongwu Securities has indicated that the company has several catalysts in the second half of the year, with multiple important clinical data expected to be disclosed [1] - The company is projected to read out top-line data for ASC30 oral Phase II, ASC47 Phase I, and ASC50 Phase I by Q4 2025, and for ASC30 subcutaneous Phase II by Q1 2026 [1] - The company anticipates submitting 2-3 new IND applications to the FDA within the next 6-9 months, including a dual-target peptide weight loss pipeline [1]
港股异动 | 歌礼制药-B(01672)再涨超7% 公司拟斥最多3亿港元进行股份购回 机构称下半年催化剂较多